(Press-News.org) CHAPEL HILL, N.C. – Diabetes is a progressive disease that affects one’s ability to control blood sugar levels. For many patients, the condition becomes more severe over time and blood sugar levels grow more difficult to manage. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, have granted patients more control in lowering of blood sugar.
John Buse, MD, PhD, the Verne S. Caviness Distinguished Professor of Medicine in the Division of Endocrinology and Metabolism, and an international team of researchers have presented new findings about new higher-dose formulations of oral semaglutide. Their study, which was published in The Lancet, found that once-daily oral semaglutide taken at 25 milligrams (mg) and 50 mg did a better job in lowering blood sugar levels and promoting weight loss than the lowest dose of 14 mg.
“Low doses of GLP-1 receptor agonists are really powerful for reducing A1C, or the average glucose in the blood,” said Buse, who is also co-director of the NC Translational and Clinical Sciences Institute. “Whereas, the higher doses that are really good for weight reduction. On average, patients lost eight kilograms (17.5 lbs) at 50 milligrams, which is nearly twice as much weight loss that we saw with the lowest dose.”
The new study is in line with other studies, which are pushing for the use of oral GLP-1 receptor agonists as a treatment for obesity.
In total, 1,606 participants, who were on average male and of 58.2 years of age, participated in the phase three program for regulatory approval. The participants were randomized into three groups and were asked to take oral semaglutide once a day. Each group took a different dosage of semaglutide, either a 14 mg dosage, a 25 mg dosage, or a 50 mg dosage, for 52 weeks.
Blood sugar levels are measured through a percentage, called A1C. According to the American Diabetes Association, most adults with diabetes need to have an A1C that is less than 7% to be considered healthy. All of the participants in the trial had an A1C between 8.0% and 10.5%. Researchers found that those who received the 25 mg and 50 mg doses of oral semaglutide were more likely to reach the A1C target of <7.0%, compared with those who took 14 mg.
Semaglutide also causes weight loss by suppressing appetite. At the end of the 52 weeks, the participants who took 50 mg of oral semaglutide had lost, on average, 17.5 pounds. Those who took 25 mg and 14 mg lost about 14.8 pounds and 10 pounds, respectively.
Over the course of the trial, researchers took note of side effects. The most common side effect was nausea, owing to the effect that the drug has on the fullness of the stomach. Some of the participants, particularly those who took the higher doses of 25 mg and 50 mg, experienced vomiting, diarrhea, and/or constipation.
END
Higher doses of oral semaglutide improves blood sugar control and weight loss
A multicenter, randomized, phase 3b trial, done in collaboration with a UNC School of Medicine researcher, found that once-daily oral semaglutide taken at higher doses of 25mg and 50mg improved regulation of blood sugar levels and weight loss compared to
2023-06-27
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Age of those with mismatched biological sex and gender identity (gender dysphoria) is falling
2023-06-27
The age of those who are distressed because of a mismatch between their biological sex and their gender identity—known as gender dysphoria—has been steadily falling, reveals research published in the open access journal General Psychiatry.
And it’s lower for those assigned female sex at birth than those assigned male, the findings indicate.
Recent studies suggest that gender dysphoria is becoming more common, particularly among those assigned female sex at birth. But these studies have been hampered by small sample sizes, short monitoring periods, or outdated datasets.
In a bid to get round these limitations, the researchers drew on data submitted ...
Mediation’s role in parental disputes about child’s medical treatment may have been oversold
2023-06-27
The role of mediation in preventing disputes between parents and doctors about a seriously ill child’s medical treatment from escalating to litigation may be more limited than hoped for, suggests an analysis of rulings, published online in the Archives of Disease in Childhood.
It might have avoided only just under half of these published court cases heard since 1990 in England and Wales, the analysis suggests.
Contested medical treatment decisions for children litigated in the courts of England and Wales may be on the rise, say the researchers.
While 10 and 11 such ...
Ask us how to build the circular economy, say scientists
2023-06-27
Governments and companies planning to pursue the circular economy need to involve scientists more directly, states a new report published by the International Society for Industrial Ecology, and led by UCL’s Dr Stijn van Ewijk.
The report, published today, draws attention to the weight of relevant expertise found in the field of industrial ecology, a discipline that has been focusing on the minimisation of waste, predicting the impacts of new products, and designing environmentally friendly systems for decades.
The ...
DNA discovery may assist in fight against aggressive cancer
2023-06-27
In a significant development in the fight against fatal cancers, University of Otago researchers have pinpointed a key feature that leads to the aggressive spread of colon cancer.
Led by Associate Professor Aniruddha Chatterjee and Drs Euan Rodger and Rachel Purcell, researchers discovered abnormalities in the DNA instruction code that lead to the aggressive spread of colorectal (bowel) cancer – Aotearoa’s second highest cause of cancer death.
Dr Rodger says the finding – published in the Cell Press journal ...
Addressing health in areas characterized by persistent poverty
2023-06-27
The Center for Health Outcomes and Population Equity (HOPE) at Huntsman Cancer Institute and the University of Utah (the U), in partnership with the Montana State University Center for American Indian and Rural Health Equity (CAIRHE), received a grant for Cancer Control in Persistent Poverty Areas from the National Cancer Institute (NCI), part of the National Institutes of Health. The new grant is part of the National Cancer Moonshot, led by the Biden-Harris Administration, and it will bring together the expertise of the Center for HOPE and CAIRHE to expand their impact through two initiatives that ...
Toxic ideas online are spreading and growing through the use of irony, analysis shows
2023-06-26
Irony has become a medium for the spread of toxic ideas online, new analysis shows.
The use of irony is growing in both contemporary politics and radical online communities because it helps people to make sense of and navigate major political and economic changes, researchers have said.
Ideas, jokes, memes, images are emerging as an animating force for new social movements and are now inextricably intertwined with the rise of the alt-right.
The study says examining irony can help understand how recent influential political ...
Validation Institute confirms over $2,200 per member per year savings from Ochsner Digital Medicine
2023-06-26
June 26, 2023 - New Orleans - Ochsner Digital Medicine has achieved Validation for Savings by the Validation Institute, an independent non-profit organization. The Institute confirmed in a new propensity-matched study that members of Ochsner Connected Health’s chronic disease management program have lower per member per month costs than similar non-participants.
"The Validation Institute has recognized what our clients and thousands of Ochsner Digital Medicine members know – this digital platform empowers members to save money, which is achieved through managing their chronic conditions ...
Mayo Clinic uses genomic testing broadly for rare diseases, improves patient care
2023-06-26
ROCHESTER, Minn. ¾ A Mayo Clinic study published in Journal of Translational Medicine evaluated the use of genomic testing broadly for rare diseases. With the increased use of genomic testing such as multi-gene panels, exome sequencing and genome sequencing in the past decade, there is a greater opportunity to better diagnose and treat patients with rare diseases. According to the National Institutes of Health, as many as 10,000 distinct rare diseases exist and an estimated 25-30 million Americans are affected by one of them.
In the four-year Mayo Clinic study, researchers evaluated 1,152 patients with rare ...
The ISSCR statement on new research with embryo models
2023-06-26
The ISSCR supports research with embryo models derived from human pluripotent stem cells that is conducted with scientific and ethical rigor. ISSCR encourages researchers to continue to follow the ISSCR Guidelines for Stem Cell Research and Clinical Translation when considering research in this emerging area. Recent work presented at the ISSCR 2023 Annual Meeting in Boston, USA this month and additional research posted online as preprints shortly thereafter highlights the rapid pace of progress in the development of stem cell-based ...
Virginia Tech study reveals reason hellbenders are disappearing
2023-06-26
The gigantic, slimy salamanders known as hellbenders, once the apex predators of many freshwater streams, have been in decline for decades, their population constantly shrinking. No one knew why. William Hopkins, professor in the Department of Fish and Wildlife Conservation and director of the Global Change Center at Virginia Tech, suspected the hellbenders’ plight had connections with environmental changes engineered by humans.
Hellbender males select nesting sites on stream bottoms and guard the eggs laid there by females — and occasionally the salamander dads snack on the eggs, consuming ...
LAST 30 PRESS RELEASES:
People with sensitive personalities more likely to experience mental health problems
Want to improve early detection of diabetes? Look in the same households as those with abnormal blood sugar
Unveiling the gut-heart connection: The role of microbiota in heart failure
Breakthrough insights into tumor angiogenesis and endothelial cell origins
Unlocking the power of mitochondrial biogenesis to combat acute kidney injury
MIT study sheds light on graphite’s lifespan in nuclear reactors
The role of fucosylation in digestive diseases and cancer
Meet Allie, the AI-powered chess bot trained on data from 91 million games
Students’ image tool offers sharper signs, earlier detection in the lab or from space
UBC Okanagan study suggests fasting effects on the body are not the same for everyone
Children’s Hospital of Philadelphia and Children’s Hospital Colorado researchers conduct first prospective study of pediatric EoE patients and disease progression
Harnessing VR to prevent substance use relapse
The 8,000-year history recorded in Great Salt Lake sediments
To craft early tools, ancient human relatives transported stones over long distances 600,000 years earlier than previously thought
Human embryo implantation recorded in real time for the first time
70 years of data show adaptation reducing Europe’s flood losses
Recapitulating egg and sperm development in the dish
Study reveals benefits of traditional Himalayan crops
Scientist uncover hidden immune “hubs” that drive joint damage in rheumatoid arthritis
Congress of Neurological Surgeons releases first guidelines on the care of patients with functioning pituitary adenomas
New discovery could lower heart attack and stroke risk for people with type 2 diabetes
Tumor electrophysiology in precision tumor therapy
AI revolution in medicine: how large language models are transforming drug development
Hidden contamination in DNA extraction kits threatens accuracy of global zoonotic surveillance
Slicing and dictionaries: a new approach to medical big data
60 percent of the world’s land area is in a precarious state
Thousands of kids in mental health crisis are stuck for days in hospital emergency rooms, study finds
Prices and affordability of essential medicines in 72 low-, middle-, and high-income markets
Space mice babies
FastUKB: A revolutionary tool for simplifying UK Biobank data analysis
[Press-News.org] Higher doses of oral semaglutide improves blood sugar control and weight lossA multicenter, randomized, phase 3b trial, done in collaboration with a UNC School of Medicine researcher, found that once-daily oral semaglutide taken at higher doses of 25mg and 50mg improved regulation of blood sugar levels and weight loss compared to